Last reviewed · How we verify
NCT06668493: LUNAR
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Phase 1, PHASE2 trial testing Nadofaragene Firadenovec in Low-grade Upper Tract Urothelial Carcinoma in 20 participants. Currently enrolling.
30 November 2029
Quick facts
| Lead sponsor | Ferring Pharmaceuticals |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 12 June 2025 |
| Primary completion | 30 November 2029 |
| Estimated completion | 30 November 2029 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Nadofaragene Firadenovec — full drug profile →
Conditions studied
- Low-grade Upper Tract Urothelial Carcinoma — all drugs for Low-grade Upper Tract Urothelial Carcinoma →
Sponsor
Ferring Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Low-grade Upper Tract Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Trials and Emerging Therapeutic Paradigms in Upper-Tract Urothelial Carcinoma.
Chavarriaga J, Raman JD. · · 2026 · PMID 42073550 · DOI 10.3390/cancers18081223
Verify or expand the search:
- PubMed search for NCT06668493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nadofaragene Firadenovec
Trials testing the same drug.
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting
- NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
Other Ferring Pharmaceuticals trials
Trials by the same sponsor.
- NCT07152730 — A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump · Phase 1 · withdrawn
- NCT07029451 — To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt · recruiting
- NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
- NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting
- NCT06561958 — Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulati · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06668493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ferring Pharmaceuticals
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing